Marx Biotechnology

Company Overview

Snapshot

Founded in January 2011 by Stephen Marx Ph.D., Marx Biotechnology operates with 1–10 employees. The company has raised $1.22M across three disclosed funding rounds from one investor. In September 2019, Marx Biotechnology secured a grant from EU Horizon 2020.

Business overview

Marx Biotechnology (MBT) develops a blood test designed to diagnose the early onset of graft-versus-host disease (GVHD), aiming to improve patient care, reduce costs, and enable rapid, accurate clinical decisions. The company's core technology involves monitoring molecular functions to detect GVHD onset, providing results to physicians within two hours. MBT also utilizes a big data platform for diagnosing various diseases, monitoring patient conditions, and guiding treatment strategies. The company serves the healthcare industry, specifically targeting laboratories and providers within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Marx Biotechnology's primary product?

Marx Biotechnology's primary product is Iris-GVHDTM, a blood test designed to diagnose the early onset of graft-versus-host disease (GVHD).

When was Marx Biotechnology founded and by whom?

Marx Biotechnology was founded in January 2011 by Stephen Marx Ph.D., who serves as the Founder & CEO.

What is the total capital raised by Marx Biotechnology?

Marx Biotechnology has raised a total of $1.22M across its funding rounds.

Has Marx Biotechnology received any grants?

In September 2019, Marx Biotechnology secured a grant from EU Horizon 2020, which contributed $50,000 in funding.

What is the current stage of Marx Biotechnology's product development?

Marx Biotechnology's product, Iris-GVHDTM, is currently in the R&D stage of development.